


Levalbuterol hydrochloride

Cat. No.:	HY-B1675A
CAS No.:	50293-90-8
Molecular Formula:	C ₁₃ H ₂₂ ClNO ₃
Molecular Weight:	275.77
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 100 mg/mL (362.62 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg	
				1 mM	3.6262 mL	18.1311 mL	36.2621 mL
				5 mM	0.7252 mL	3.6262 mL	7.2524 mL
				10 mM	0.3626 mL	1.8131 mL	3.6262 mL
Please refer to the solubility information to select the appropriate solvent.							
In Vivo	1. Add each solvent one by one: PBS Solubility: 100 mg/mL (362.62 mM); Clear solution; Need ultrasonic						

BIOLOGICAL ACTIVITY

Description	Levalbuterol ((R)-Albuterol) hydrochloride is a short-acting β ₂ -adrenergic receptor agonist and the active (R)-enantiomer of Salbutamol. Levalbuterol hydrochloride is a more potent bronchodilator than Salbutamol and has the potential for the treatment of COPD ^[1] .	
In Vitro	Levalbuterol (10 μM; 24 hours) hydrochloride induces 11β-HSD1 mRNA expression, however, it does not influence 11β-HSD2 expression in airway epithelial cells ^[1] . Levalbuterol (10 μM; 24 hours) hydrochloride significantly reduces both LPS- and TNF-α-induced NF-κB activity while increasing GRE activation in an 11β-HSD1 dependent manner in a transformed mouse airway epithelial cell line ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. RT-PCR ^[1]	
	Cell Line:	Murine Club (MTCC) cells

	Concentration:	10 μ M
	Incubation Time:	24 hours
	Result:	Increased 11 β -HSD1 mRNA expression selectively.
In Vivo	<p>Levalbuterol (subcutaneous injection; 1 mg/kg; 14 days) hydrochloride significantly decreases pulmonary inflammation in OVA mice, demonstrated a decrease in eosinophilia and IgE^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	
	Animal Model:	C57BL/6 female mice with a pulmonary allergic model ^[2]
	Dosage:	1 mg/kg
	Administration:	Subcutaneous injection; 1 mg/kg; 14 days
	Result:	Decreased pulmonary inflammation after OVA sensitization.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA